Skip to main content

Schedule 2017

With the biggest and best line up of conference speakers we have ever assembled the 2017 LDN Conference will, without doubt, be the best yet.

Below is the confirmed line up for all 3 days.

Exhibitors Opening Times

Friday and Saturday

8.30 Exhibitors Open | 6.30 Exhibitors Close

Sunday

8.30 Exhibitors Open | 2.30 Exhibitors Close

To view the bio of the speakers click on their picture or go to the speakers page.

9:00 - 9:05

Welcome

Linda Elsegood

9:05 - 9:10

Introduction

Dr. Mark Mandel

9:10 - 9:55

Using an Old Drug to Trick the Immune System into Healing Itself

Pharmacist Stephen Dickson

Covering the historical uses, background, and complex issues surrounding Naltrexone. A more in-depth review and discussion of evidence published in The LDN Book. This lecture gives a background to health professionals in the complex interacting biological pathways involved in using Naltrexone in autoimmune diseases and cancer.

9:50 - 10:25

New Cost-Effective Treatment for Autoimmune Illnesses, Cancer, and Chronic Diseases?

Dr. Nasha Winters

Today LDN therapy has gained traction in many arenas. Conventional pharmaceuticals are utilizing LDN combined with medications. Integrative/functional medicine practices are beginning to embrace LDN therapy. The interest in LDN is growing in people who are suffering from autoimmune conditions, cancer, and other chronic diseases. LDN offers many advantages including cost-effectiveness. Today, LDN therapy can be administered for less than a dollar per day in the U.D. through compounding pharmacies. Therefore, the potential cost-saving of LDN therapy for many conditions are enormous. This presentation will focus on the role of LDN as a novel anti-inflammatory agent for the central nervous system, the role of LDN for treating endorphin deficiency syndromes, LDN as immuno-adaptogen, and atypical uses of LDN therapy.

10:25 - 10:45

Morning Break

A short 20 minute break

10:45 - 11:30

The Role of the Opioid System in Immune-Mediated Disease

Dr. Anthony Turel

The purpose of this presentation is to provide a scientific explanation regarding the various receptors in the opioid system and their potential role in modulating the effects of immune disorders. The biological effect of the opioid receptor antagonist naltrexone will be explained, and its unique properties discussed.

11:45 - 12:45

Q&A

The Q&A Panel

11:30 - 11:45

Multiple Sclerosis: Result-Based Immune Therapies Beyond Those Normally Offered

Paul S. Anderson, NMD

Multiple Sclerosis is an incredibly common autoimmune condition which has limited treatment options in standard medicine. For the last three decades, Dr. Anderson has treated patients with Multiple Sclerosis in and integrative setting with greatly improved outcomes in most cases. In this session, he will share the outline of his integrated care and the latest cutting edge additions to these therapies.

12:45 - 13:45

Lunch

A one hour break for lunch

1:45 - 2:00

Modern laboratory tests for diagnosing Lyme disease

Dr Armin Schwarzbach

Lyme disease is like a ‘chameleon’ of symptoms and laboratory tests. Chronic multiple symptoms of Lyme disease can include: chronic fatigue, joint and muscle pain, neck-pain, neurological symptoms like burning hands/feet or sensitivity problems, sleeplessness, short-term memory loss, concentration problems, psychiatric problems like aggressiveness or anxiety, autoimmune disorders. Chronic Lyme disease can be attributed to so-called unexplained syndromes like Chronic Fatigue Syndrome, Myalgic Encephalitis, Amyotrophic Lateral Sclerosis, Multiple Sclerosis, Alzheimer’s, Parkinsonism, Rheumatoid Arthritis, Sjögren's Syndrome, Hashimoto thyroiditis, tinnitus, depression, schizophrenia, Carpal Tunnel Syndrome, Autism.

There is a lack of confidence in falsely established laboratory tests for antibodies like the Borrelia-ELISA test or Borrelia Westernblots, which are not standardized and very often false-negative. Doctors need the practical help by better and improved laboratory tests, such the SeraSpot (modern Borrelia Westernblot), EliSpot (modern T-cell test) and CD57-cells. The modern microarray SeraSpot offers a better standardization in comparison with normal Westernblot tests, shows an improved sensitivity by using the new MicroArray analytics and covers all 3 main Borrelia subspecies (Borrelia sensu stricto, Borrelia garinii and Borrelia afzelii) by combining recombinant and native Borrelia antigens. The Elispot reflects the current activity of Borrelia burgdorferi and covers all 3 main Borrelia subspecies by combining recombinant and native Borrelia antigens. The CD57-cells reflect the chronic activity of Borrelia burgdorferi and show in newer studies correlations with Autism too. The presentation will describe all modern analytical laboratory test possibilities: SeraSpot, EliSpot and CD57-cells. 

2:00 - 2:45

Immune Dysfunction and Chronic Lyme Disease

Dr. Kent Holthorf

Chronic Lyme disease is the fastest growing vector-borne illness in the country, with more cases diagnosed per year than HIV and breast cancer combined. However, because diagnosing Lyme can be difficult, many people who actually have Lyme may be misdiagnosed with other conditions such as chronic fatigue syndrome, fibromyalgia, lupus, multiple sclerosis, mixed connective tissue disease, depression, bipolar depression, seizure disorder, ALS, Alzheimer's IBS, and rheumatoid arthritis. Many experts believe the true number of cases is much higher. A hallmark of chronic Lyme disease is an underlying immune dysfunction that not only limits the ability to accurately diagnose Lyme, leaving many such patients misdiagnosed, but also serves as a major reason for lack of treatment response to antibiotics with an inability to eradicate the chronic infection.

The Borrelia bacteria (cause of Lyme disease) transforms from an acute to a chronic infection by transforming the body to a TH2 "extracellular" dominant response and then converting from a free swimming spirochete form in the blood into an intracellular form (L-form) to escape the elevated TH2 immunity. The suppressed and down-regulated TH1 intracellular immune response becomes an ineffective immune response by the body and an effective evasion strategy, which is the hallmark of transformation to late-stage Lyme dissemination. While there are many controversies surrounding the diagnosis of chronic Lyme disease, identification of this immune dysfunction that is consistently found in this illness can greatly aid in the diagnosis of tick-borne illness and to identify the stage and even severity of Lyme disease. The level of immune dysfunction may also be the single most important determinant of treatment success. Thus, appropriate immune modulating therapies that are able to restore normal functioning immunity may be the biggest necessary leap forward in the development of an effective treatment protocol for this multi-system illness.

2:45 - 3:00

A Novel Approach to Type 1 Diabetes Mellitus

Paul Battle

Description:  P.A. Battle will present a case where a 10-year-old girl with Diabetes type 1 was not controlled with an insulin pump and strict diet. After LDN was introduced into her regimen, her diabetes was controlled, with less insulin requirements.

3:00 - 3:20

Afternoon Break

A short 20 minute break

3:20 3:50

Children are not Small Adults: Considerations for Medication Dosing and Delivery

Dr. Deanna Windham

The session explores dosing and delivery recommendations for children on less common medications.

3:50 - 4:05

Psoriasis: A Novel Approach to Treatment

Dr. Deanna Windham

Explores the science behind the newest modalities of treatment for psoriasis with case studies and recommendations.

4:05 - 4:20

Navigating the Narrative with your Health Care Team

Dr. Nasha Winters

This discussion offers insight on how to articulate the need and application of LDN respectfully and thoughtfully with your health care team in order to create a common language in the medical system, and the ability to receive access to this powerful medicine.

4:20 - 5:20

Q&A

The Q&A Panel

7-8pm

Laughter Yoga Course

Jill Brook, M.A.

9:00 9:05

Welcome

Linda Elsegood

9:05 - 9:10

Introduction

Dr. Mark Mandel

9:10 10:10

Approach to Managing Chronic Pain

Dr. Pradeep Chopra

Understanding the mechanism of chronic pain with a focus on neuropathic pain. The presentation will discuss the mechanism of autoimmune mediated chronic pain and treatment strategies.

10:10 - 10:30

Morning Break

A short 20 minute break

10:30 - 11:00

The Ten Most Important Fibromyalgia Discoveries of 2016 and 2017

Dr. Jarred Younger

Research into fibromyalgia has increased dramatically in the past few years, with 50 new studies being published every month. Fibromyalgia now attracts the interest of researchers across many scientific disciplines, increasing the chances that we can make substantial progress in the near future. We will discuss the ten most significant scientific reports in fibromyalgia over 2016 and 2017, covering studies in fields such as clinical trials, immunology, neuroimaging, genetics, endocrinology, psychology, and epidemiology. The discussed studies will represent the most important advances in fibromyalgia diagnosis and treatment. We will conclude with a description of the next steps in fibromyalgia research, and what we can expect in the next few years.

11:00 - 11:15

Turning Down the Volume on Fibromyalgia Pain

Dr. Ginevra Liptan

Fibromyalgia is a common condition of widespread pain reflecting central nervous system sensitization. Fibromyalgia pain is notoriously resistant to standard treatments, in part because they do not address the key contribution of the glial cells, the support and immune cells that surround neurons. Central sensitization is a complex process resulting in abnormal glial cell activation and inflammation.

Low Dose Naltrexone (LDN) calms activated glial cells and lowers the volume of pain transmitted to the brain. Stanford University researchers found in two separate studies that LDN substantially reduced fibromyalgia pain. Clinical experience supports these research findings, and the presentation will briefly review two eyars of data from the use of LDN in a fibromyalgia specialty practice.

11:15 - 11:30

Physiology and Treatment of Postcoital Dysphoria

Dr. Mark Shukhman

Changes in mood following sexual intercourse or other sexual experiences is a well-described phenomenon, which is surprisingly common. Most of the time, it is not recognized as a physiological consequence, because of the tendency to explain it with psychological or psycho-social reasons. In fact, in addition to the psychology of the phenomenon, the role of dopamine and endorphins, along with the multitude of other neurotransmitters, is hypothesized in the literature. This presentation will focus on Low Dose Naltrexone, an opioid receptors modulator, as a remedy to lessen the effect.

11:30 - 12:15

Q&A

The Q&A Panel

12:15 - 1:15

Lunch

A one hour break for lunch

1:15 - 2:15

Irritable Bowel Syndrome: The Roles of Small Intestinal Bacterial Overgrowth (SIBO) and Mucosal/Systemic Inflammation

Dr. Leonard Weinstock

In the last 16 years there is a shift in the paradigm of understanding the pathophysiology and treatment of irritable bowel syndrome (IBS). Two key factors in the pathophysiology are small intestinal bacterial overgrowth and mucosal/systemic inflammation. A significant portion of irritable bowel syndrome is due to SIBO and dysbiosis. The nature of the gases produced by bacterial fermentation change the presentation of the bowel symptoms. The underlying cause of post-infectious IBS and the application to IBS in general is a major development–-autoimmune IBS is a newly recognized condition that takes the S out of IBS and makes us able to call it a disease.

2:15 - 2:30

Crohn's Disease: Latest Integrative Immunologic Therapies

Paul S. Anderson, NMD

Crohn's Disease is an incredibly common autoimmune digestive system condition which has limited treatment options in standard medicine. For the last three decades, Dr. Anderson has treated patients with Crohn's Disease in an integrative setting with greatly improved outcomes in most cases. In this session, he will share the outline of his integrated care and the latest cutting edge additions to these therapies.

2:30 - 2:45

Fire in the Hole--Intestinal Permeability, The Development of Autoimmune Disease, and a Comprehensive Approach to Healing the Gut

Dr. Tom O'Bryan

Autoimmune diseases are a primary cause of morbidity and mortality in the industrialized world. That means it's in our offices every day. The number of people diagnosed with an autoimmune disease is increasing exponentially in our country. Estimates are that anywhere from three to seven out of every ten new patients coming into your office are suffering from an autoimmune mechanism (whether it has been recognized and diagnosed or not). The volume of information now of the underlying mechanisms that set the stage and contribute to the development of autoimmune disease is overwhelming.

Without recognizing and addressing the underlying mechanisms triggering the presenting complaints, the Practitioner may be proverbially 'chasing the tail' of the pathology with temporary symptom relief. The Practitioner who has a deep understanding as to when to suspect an immune reaction to an environmental trigger, has access to thorough testing tools, and who also understands and supplies comprehensive treatment protocols, that Practitioner will see results in their Practice like never before. This Presentation will outline the Trilogy in the development of autoimmune disease and its musculoskeletal/neurological presentations with a deep emphasis on testing and treatment protocols that have consistently demonstrated dramatic results.

2:45 - 3:00

What the Bleep Can I Eat?! Making Sense of Conflicting Autoimmune Diets

Jill Brook, M.A.

This short presentation will introduce several different nutritional approaches to managing autoimmune disorders, and explain how each plan takes a different approach:

  • Anti-inflammatory basics
  • Paleo Autoimmune Protocol
  • Low FODMAP
  • Low Histamine
  • Low Sulpher
  • Specific Carbohydrate Diet 

LDN dietary tips It will give a quick explanation of which conditions may benefit most from each nutrition plan.

3:00 - 3:20

Afternoon Break

A short 20 minute break

3:20 - 3:50

The Role of Non-Cytotoxic Drugs in the Management of Cancer

Professor Angus Dalgleish

It is becoming clear that drugs other than cytotoxic chemotherapy agents have a major impact on certain cancer types. Our team has researched a number of these agents, how they can be useful alone and in combination with other drugs and other modalities. These include the Artemisinins, and we are particularly focused on Artusenate, which is in small clinical trials in colorectal cancer.  Another group of drugs that appear to be effective in certain cancer types are based on the Cannabinoids. Our own group has shown that these can have marked inhibition of cell lines, without being cytotoxic, but more importantly, on withdrawal of the drug, the cell lines become much more susceptible to cell death and being killed by other modalities. Our group has shown that cannabinoids, in certain mixtures, can greatly enhance the sensitivity of murine gliomas to radiotherapy and this has obvious clinical translation possibilities.

Another agent that can have similar cytostatic properties and effect on the immune response without having direct anti-cancer effect is Naltrexone, where the effect is more evident at lower doses. We have shown that in addition to using a different group of receptors other than the opiates (certain Toll-like receptors) it also has a markedly different effect on gene expression, whether the low or high dose or normal therapeutic dose is used.

These and other drugs that affect inflammation and metabolism, such as a variety of anti-inflammatory agents, which include Aspirin and statins, as well as metabolic agents such as Metformin, in addition to several other widely used agents that have marked anti-cancer activity in their own right, such as Doxycycline and anthelmintic treatment, may make all the difference in enhancing outcome when added into, supplementing, other treatments.

3:50 - 4:20

Broad spectrum, Gentler Anti-Neoplastics: Breaking the cycle of toxic therapy

Dr Akbar Khan

This presentation will cover the use of re-purposed drugs that have broad spectrum anti-cancer activity through various mechanisms, and are also non-toxic unlike conventional chemotherapy. Various therapies will be reviewed, with an emphasis on oral low dose naltrexone (other therapies include dichloroacetate and dimethylsulfoxide).

4:20 - 5:20

Q&A

The Q&A Panel

7.30pm - 10pm

Networking Party

The LDN Team

9:00 - 9:05

Welcome

Linda Elsegood

9:05 - 9:10

Introduction

Dr. Mark Mandel

9:10 9:25

Thyroid Autoimmunity: Causal Relationships & Novel Therapeutics

Dr. John A. Robinson

It is well known that autoimmunity is the leading cause of thyroid dysfunction in the developed Western world. The goal of any comprehensive thyroid treatment approach should consider the step before the autoimmunity leading to a Tolle Causum, or Treat the Cause, approach to the philosophical and intellectual approach of the physician. In addition, both novel and traditional approaches to thyroid disease management exist that offer an often highly advantageous and superior treatment alternative. This lecture will present clinical evidence of patient improvement and health optimization in respect to thyroid function and metabolism while undergoing a comprehensive treatment that treats the cause. The clinical evidence of improvement/non-improvement will be reported through the measurement of various markers including serum thyroid autoantibodies including anti-thyroidperoxidase (anti-TPO), anti-thyroglobulin (anti-TG), CRP (C- Reactive Protein), RBC sedimentation rate, serum IgG (Immunoglobulin G) reactions to ingested foods, brachioradialis reflex speed, resting metabolic rate as measured by indirect calorimetry, and patient self-reporting of symptoms, among other measurements.

9:25 9:40

Vitamin D and Autoimmune Disease: A Systematic Review of the Literature

Jill Cottell, MD

Vitamin D deficiency has been shown to be a risk factor for a number of medical illnesses, including autoimmune disease. Because of this link, many practitioners routinely recommend vitamin D supplementation to their patients. Is there really any evidence to support this practice, and what are the benefits and risks associated with vitamin D treatment? We will examine the evidence in a systematic review of the literature.

9:40 - 10:10

Treating the Zebras in Primary Care

Jill Cottell, MD

Across the globe, autoimmune disease is on the rise at an alarming rate.  Patients are facing treatment options that are expensive and fraught with many potential side effects.  Many of them are learning about low dose naltrexone for the first time, and they are coming to their primary care provider with questions.  We need to be able to answer these questions and provide them with the care they deserve.

10:10 - 10:40

Review of Recent Statistics for Patients Taking LDN in a Special Needs Pediatric Practice

Dr. Brian Udell

This session will review factors affecting the success of LDN as a treatment including: accurate diagnosis, choosing candidates most likely to succeed, addressing gut and metabolic issues first, and addressing other co-morbidities as they exist or arise.

11:00 - 11:30

Opioid Antagonists and Traumatic Brain Injury

Ulrich Lanius, Ph.D. and Galyn Forster, MS, LPC

Review of recent research and controversies regarding the use of opioid antagonists as treatment interventions for the effects of Traumatic Brain Injury (TBI/MTBI). A number of case studies are presented and timing of interventions and preliminary dosing strategies are discussed. It is suggested that opioid antagonists may potentially be an effective intervention for the effects of TBI/MTBI.

11:30 - 11:45

A Medication to Gain Self-Awareness: Treatment of Dissociative Symptoms in Trauma-Related Disorders

Dr. Wiebke Pape

Dissociative symptoms (like derealisation, emotional numbing, 'losing time,' the lack of self-awareness) occur in most of the cases of trauma-related disorders. Psychotherapeutic treatment is difficult and slow-moving, and there is hardly any pharmacologic strategy that is recommended.

Following the hypothesis that blocking opioid receptors leads to a decline in opiate modulated dissociative phenomena, since 1999 experiences with naltrexone as medication for dissociative symptoms have been gained (mainly in a dose of 25 to 100 mg/d). In this presentation, first experiences with LDN (2-6 mg/d) in the treatment of patients with severe trauma-related and dissociative disorders will be described.

The low dose treatment with naltrexone proved to be effective: 11 out of 15 patients reported immediate positive effects, 7 described a lasting helpful effect. The majority of patients who felt positive effects reported a clearer perception of both their surroundings as well as of their inner life. Assessment of reality and dealing with it improved, as did the perception of their own body and affects as well as self-regulation. The treatment was very low in side effects.

Treatment with low dose naltrexone may be a helpful element in the treatment of patients with complex posttraumatic stress disorder. However, it has to be realized that the decrease of dissociation may lead patients to a not yet resolvable challenge, in as much as dissociation had previously been a necessary mechanism of self-protection.

11:45 - Noon

A Guide to Testing Steroid and Peptide Hormones in Different Body Fluids

Dr. David T. Zava

Hormone therapy is a mainstay in treatment of hormonal imbalances and helps guide and optimize the type, dosage, and delivery of the hormone. Hormone therapy without first testing hormone levels can lead to less than optimal therapy.

Hormone testing for steroid hormones is most commonly performed using venipuncture serum or plasma and urine.  Other body fluids (saliva and fingertip capillary dried blood spots-DBS) are becoming more commonplace due to convenience of collection and more accurate assessment of bioavailable hormone levels.

In this lecture I will discuss the pros and cons of using different body fluids and methods (EIA vs LC-MS/MS) for testing steroid hormones, produced endogenously or taken exogenously by different routes of administration (oral, topical, troche, sc pellets, etc.).  I will explain why most body fluids are appropriate for hormone testing following exogenous hormone supplementation but that serum and urine are less optimal than saliva and capillary blood for detecting hormones following topical hormone delivery. 

Noon - 12:15

LDN and Pets

Dr. Mark Mandel

12:15 - 1:15

Q&A

The Q&A Panel

1:15 1:25

Summary

Dr. Mark Mandel

Available September 2017

The Role of Enkephalins in the Pathophysiology of Multiple Sclerosis: What We Can Learn From Mouse Models

Michael Lugwig

Enkephalins are endogenous compounds secreted as prohormones, post-translationally modified into small neuropeptides, and widely distributed. There are multiple enkephalins, but methionine-enkephalin, also termed opioid growth factor (OGF) is highlighted as a neurotransmitter and ubiquitous inhibitory growth factor. The latter function is mediated by a nuclear-associated receptor termed OGFr. The OGF-OGFr regulatory pathway is prominent in most mammalian tissues, playing a significant role in mediating cellular homeostasis. If dysregulated by disease, the OGF-OGFr pathway becomes a target pathway for treatment. To bring new drugs and therapies to the clinic, preclinical studies must establish the efficacy and possible mechanism of action. With regard to multiple sclerosis, the primary animal model is experimental autoimmune encephalomyelitis (EAE), and can be established to mimic both chronic progressive or relapsing-remitting forms of MS. induction of chronic progressive EAE by immunization with myelin oligodendrocytic glycoprotein (MOG35-55) is the most consistent animal model, whereas the relapsing-remitting form of EAE can be induced by immunization with proteolipid protein (PLP139-151). The pro-inflammatory components of both EAE and MS are similar, as the levels of IFN-γ , IL-1β, and TNF-α are upregulated, thus validating the models for study of the pathophysiology of disease. Our research has focused on the role of enkelphalins, specifically OGF, in both the onset of disease and the response to therapy. We have demonstrated that both exogenous and endogenous upregulation of OGF reduces clinical signs of disease and decreases resulting pathology (activated astrocytes, demyelination, and neuronal damage). The role of OGF as an inhibitor of cell replication has been validated with in vitro studies of activated lymphocytes. The finding of low serum enkephalin levels in both humans and animals has substantiated our hypothesis that MS/EAE is associated with a dysregulated OGF-OGFr pathway, and that enkephalins serve as biomarkers for disease progression and response to therapy. 

Available September 2017

Fire in the Hole--Intestinal Permeability, The Development of Autoimmune Disease, and a Comprehensive Approach to Healing the Gut

Dr. Tom O'Bryan

Autoimmune diseases are a primary cause of morbidity and mortality in the industrialized world. That means it's in our offices every day. The number of people diagnosed with an autoimmune disease is increasing exponentially in our country. Estimates are that anywhere from three to seven out of every ten new patients coming into your office are suffering from an autoimmune mechanism (whether it has been recognized and diagnosed or not). The volume of information now of the underlying mechanisms that set the stage and contribute to the development of autoimmune disease is overwhelming.

Available September 2017

Dissociative Symptoms in Trauma-Related Disorders: A Closer Look at the Possibilities of a New Medication

Dr. Wiebke Pape

Dissociative symptoms (like derealisation, emotional numbing, 'losing time,' the lack of self-awareness) occur in most of the cases of trauma-related disorders. Psychotherapeutic treatment is difficult and slow-moving and there is hardly any pharmacologic strategy that is recommended.

First experiences with the use of LDN as a supportive medication showed that it can be a very helpful element in the treatment on the whole. Compared to previously used drugs in treating dissociation and complex PTSD there is 'something new' about the effects that occur with patients who profit by being treated with LDN. It is not only the fact that a worrying symptomatic declines, but it seems as if a new connection is arising between cognitive thinking and emotional perception which may lead to an improvement of self-awareness, and deepened self-reflection, and a growth of self-empathy.

A first conclusion with respect to 6 years of using LDN may be that it is a 'psychotherapeutic drug' as it helps to get in touch with inner life, and 'the suffering that one had to bear.' It can be a support considering the effort of psychotherapy to develop strategies of self-care and a benevolent attitude toward oneself.

Available September 2017

Thyroid Disease: Optimizing Metabolism Through Comprehensive Hormonal Treatment

Dr. John A. Robinson

Thyroid hormone affects the overall metabolism of every cell within the human body. Therefore, thyroid disorders are metabolic disorders. Therapeutic interventions for thyroid disease realize their best outcomes when seen through the lens of optimizing metabolic rate. This lecture will expound on this concept demonstrating direct therapeutic strategies and tools for measuring and enhancing metabolic rate. The physician will learn how to accurately measure metabolic rate clinically and how to alter this rate with optimal thyroid hormone interventions. Additionally, this lecture will demonstrate the biological interrelationships with various hormonal systems including sex hormones, insulin and blood sugar regulation, adrenal dysfunction, and gastro-endocrine implications. The entire hormonal milieu will considered in the context of its influence on thyroid hormone metabolism and function and the resultant benefits to metabolic rate and patient symptomatic improvement.

Available September 2017

Symptoms, Modern Laboratory Tests and New Therapy Options in Chronic Lyme Disease and Coinfections

Dr Armin Schwarzbach

The laboratory diagnosis of tick-borne diseases and other symptom-related chronic infections is based on indirect and direct laboratory tests for different kinds of bacteria and viruses. In each bacterial and viral infection there should be an immune response based on antibodies and/or T-cells. There is a lack of confidence in falsely established laboratory tests for antibodies like the Borrelia ELISA, which are not standardized and often false negative. 

Diagnosing doctors need  better and improved laboratory tests, such as new microarray SeraSpot (modern Borrelia-Westernblot) and testing for T-cellular immune responses by the Elispot and CD57 cells. Many patients with tick-borne diseases have multiple infections, and most symptoms of all tick-borne diseases are not high-specific for Lyme disease or one of the other tick-borne diseases. Ticks are contaminated with Borrelia burgdorferi and other bacteria like Ehrlichia/Anaplasma, Rickettsia, Babesia and Bartonella. There are many evidence-based studies about  Borrelia burgdorferi and Chlamydia pneumoniae as the causing agents in patients with inflammatory arthritis, Multiple Sclerosis or Alzheimer's disease. This presentation provides guidance to assist clinicians in obtaining an individual clinical “ranking” of possible bacterial and viral infections, and discusses laboratory tests with the highest sensitivity and specificity for each possible bacterial and viral infection according to the “ranking” of the coinfections-checklist. This should be done before starting any antibiotic or other therapy. According individual laboratory test findings therapy options can be antibiotics, virostatics or complementary therapies. There are different herbal protocols and immune supporting therapies aiming bacterial and viral infections used by naturopaths.  

This presentation shows the clinical “grading” and “ranking” of symptoms according the digitalized coinfections-checklist and the laboratory “staging” processes in diagnosing tick-borne diseases and other infections by the help of  modern laboratory tests, shown by several case-reports and evidence-based literature for optimized therapy decisions in the complexity of multiple chronic infections. 

Available September 2017

Low Dose Naltrexone and Autism Spectrum Disorder

Dr. Brian Udell

Autism Spectrum Disorder is a complex, multi-system condition, now of epidemic numbers, leading to behavioral and developmental signs and symptoms. However, many of the signs and symptoms represent treatable conditions. A combination of therapies and medical intervention at earliest stages provides the best chance for recovery.

Available September 2017

Inflammatory Bowel Disease – Standard and New Approaches to Therapy

Dr. Leonard Weinstock

The two primary inflammatory bowel diseases (IBD) are Crohn’s disease (CD) and ulcerative colitis (UC). The pathophysiology is complex and overlaps with each other. Genetic predisposition, immune disorders and environmental triggers are thought to be the initial basis for the diseases. Autoimmune factors are involved. Treatment of Crohn’s disease includes a variety of compounds designed to reduce the inflammatory response. Although 5-ASA compounds are very safe and remain the mainstay of therapy in UC, these agents used as monotherapy often do not maintain remission in UC and do not work well in ileal Crohn’s disease. During acute attacks or flare-ups, corticosteroids augment various therapies, but these agents cannot be used for long-term maintenance due to systemic toxicity. For decades, thiopurines (azathioprine and 6-mercaptopurine) have been used to maintain remission in both CD and UC, and the availability of therapeutic blood levels facilitates the management and decreases toxicity associated with these agents. Monoclonal antibodies specific for molecules expressed by the T cell population or antibodies specific for cytokines known to be central to the pathogenesis of mucosal inflammation (i.e., anti-tumor necrosis factor, anti-TNF) are important. Unfortunately, treatment with many of these agents often leads to serious side effects and the overall, long-term success is less than 50%. Among the serious adverse events are the development of serious opportunistic infections and neoplasms, and in children or young adults a fatal condition called hepatosplenic lymphoma has been reported when these drugs are combined. When combination therapy is not satisfactory, there are several concerns and a few options that remain. Adjunctive therapies include antibiotics, probiotics, and restricted diets (elemental liquids, gluten-free, FODMAP-free, and, rarely, total parenteral nutrition). Because of the toxicity and inadequate efficacy of the immunosuppressive and biologic medications used for IBD, novel strategies that are safer are desirable.

Available September 2017

Cancer: Using the Latest Ideas in Immunotherapy to Improve Outcomes, Survival, and Quality of Life

Paul S. Anderson, NMD

Cancer is a pervasive and frightening condition the world over. Standard therapies have a place in treatment in many cases, but lack widespread efficacy and success in treatment. Dr. Anderson has spent the past three decades actively treating patients with cancer, and the past decade involved in cancer research using advanced oncology therapies. In this session, he will discuss how including the latest advances in immunotherapy advances the potential outcomes for patients with cancer.

    Available September 2017

    Celiac Disease-Associated Autoimmune, Inflammatory, and Gastrointestinal Disorders: Mechanisms and Treatment

    Dr. Leonard Weinstock

    It is critical to diagnose celiac disease to improve quality of life and prevent autoimmune diseases that are associated with it. These conditions may be avoidable if it is recognized, so that the patient does not have to suffer from thyroid diseases, Addison's disease, a variety of neurological and dermatological diseases, and diabetes. Osteoporosis may be an autoimmune disease as opposed to simple malabsorption of calcium and vitamin D in the setting of enteropathy. Along with the autoimmune phenomenon comes inflammation. This can be associated with fatigue and depression. Even after treating celiac disease with a gluten free diet, it can take 2 years before the mucosa can normalize and during this time inflammation is present. Finally, even after the mucosa is normalized, chronic GI symptoms can persist including bloating and gas. This may be due to a change in the microbiome due to a prior history of active celiac disease. Antibiotic therapy for potential small intestinal bacterial overgrowth has been disappointing. Additional therapy needs further evaluation.

    Available September 2017

    Thyroid Disorders: Latest Advances in Help and Healing

    Paul S. Anderson, NMD

    Thyroid disorders are one of the most common hormonal conditions in humans. They can affect every aspect of health and quality of life in those who suffer from them. This session will look at the propensity of thyroid problems in humans, their immune connections and how modern immunologic therapies can assist in treatment and healing. Dr. Anderson will use his many years' experience and thousands of cases to inform this session discussion and detail.

    Available September 2017

    Postural Orthostatic Tachycardia Syndrome (POTS): Pathophysiology, Gastrointestinal Involvement, and New Therapy with LDN and IV Immune Globulin

    Dr. Leonard Weinstock

    It is critical to diagnose POTS to improve quality of life and prevent severe disability associated with it. This disease is now felt to be an autonomic autoimmune disease and it affects most body systems with widespread symptomatology. This can be associated with small intestinal bacterial overgrowth.

    Available September 2017

    Nutritional Strategies for Managing Autoimmune Disorders

    Jill Brook, M.A.

    This presentation offers a practical guide to autoimmune diets, and explains how they each take different approaches to healing:

    • Anti-inflammatory basics
    • Paleo Autoimmune Protocol
    • Low FODMAP
    • Low Histamine
    • Low Sulphur
    • Specific Carbohydrate Diet
    • Other SIBO diets
    • LDN diet

    It explains the latest research, provides information on who should consider implementing which approaches (and for how long), and offers tips for making restrictive plans less burdensome.

    Available September 2017

    Lupus: A Misunderstood Disease

    Dr. Deanna Windham

    Explores the science behind the contributory factors for development of lupus then moves into new and novel therapies to approach integrative treatment.

    Available September 2017

    Treating Mental Health Issues Using Low Doses of Naltrexone as an Adjuvant to Psychotherapy and as a Stand-alone Pharmaceutical

    Dr. Ulrich F. Lanius

    Case studies of patients with a variety of psychiatric disorders treated with low dose naltrexone. Treated symptoms include hyper vigilance, anxiety, pain, depressed mood, anger outbursts, sleep difficulties, nightmares, concentration difficulties, PMS symptoms and behavioural and substance addictions. The presentation will briefly review dosing and strategies for initiating treatment of mental health issues with low dose naltrexone.

    Available September 2017

    Bipolar Disorder: Difficulties in Diagnosis and Treatment

    Dr. Deanna Windham

    Discusses the many disease processes that can mimic or destabilize bipolar disorder, how to identify and manage them.

    Available September 2017

    Treating PTSD in Military Veterans Using Low Doses of Naltrexone as an Adjuvant to Psychotherapy and as a Stand-alone Pharmaceutical

    Dr. Ulrich F. Lanius

    A collection of case studies demonstrating how low dose naltrexone can be used to reduce PTSD-related symptoms in veterans, improving both their capacity to benefit from psychotherapy and their ability to adapt and function in the civilian world. These case studies will demonstrate how LDN significantly reduced disruptive symptoms of anxiety and depression, anger outbursts, nightmares, sleep problems, etc. 

    Available September 2017

    Rebooting the Immune System: Putting the Brake on Cancer Progression

    Dr. Nasha Winters

    This discussion will highlight three cases of advanced disease responding favorably to the introduction of LDN therapy.

    Available September 2017

    An Introductory Review of the Research Exploring Opioid Antagonists as Treatment for Psychiatric Disorders

    Dr. Ulrich F. Lanius

    This presentation will summarize the results of a number of studies that have explored treatment of various mental health issues with opioid antagonists. There will be a brief discussion of the shortcomings and strengths of these studies. It is suggested that one cannot assume LDN will work identically to high doses of naltrexone, but in light of what is being learned about the efficacy of LDN, these studies hold out the possibility these disorders might respond well to LDN or, in some cases, even better than to high doses of naltrexone or naloxone.

    Available September 2017

    An Introduction to the Issue Phobia of Shared Positive Affect, How it Confounds Treatment, and How to Treat It

    Dr. Ulrich F. Lanius

    This presentation will describe the etiology of the phobia of shared positive affect, how it disrupts relationships in the lives of patients, including the clinician-patient relationship, and how to both accommodate/navigate around and treat this issue. Simple principles and guidelines will be offered to reduce its disruptiveness and begin healing this daunting but relatively easily changed phobia.

    Available September 2017

    Broad spectrum, gentler anti-neoplastic: Breaking the cycle of toxic therapy

    Dr Akbar Khan

    This presentation will cover the use of re-purposed drugs that have broad spectrum anti-cancer activity through various mechanisms, and are also non-toxic unlike conventional chemotherapy. Various therapies will be reviewed, with an emphasis on oral low dose naltrexone (other therapies include dichloroacetate and dimethylsulfoxide)

    Available September 2017

    Traumatic Stress and Dissociative Symptoms: Adjunctive Pharmacological Interventions

    Dr. Ulrich F. Lanius

    Recent research on the use of opioid antagonists for traumatic stress syndromes and dissociative symptoms is discussed. Case studies are presented that describe the adjunctive use of opioid antagonists in treatment of dissociative symptoms. Further, case studies are presented where psychiatric overlay complicates the use of opioid antagonists in the management of pain and autoimmune disorders. A neurobiological rationale for adverse effects on emotional functioning in these cases and how to address these issues are presented. Specifically different dosing strategies and their integration with psychotherapeutic interventions are discussed.

    Available September 2017

    Alternative Strategies for Alleviating Fibromyalgia Pain: Tips, Tricks, and Case Studies from a Specialty Practice

    Dr. Ginevra Liptan

    Fibromyalgia is a common condition of widespread pain reflecting central nervous system sensitization. To understand how to direct treatment of this complex illness, one needs to understand the pathophysiology leading to abnormal spinal cord amplification of pain signals, so we'll start with a brief tour of our scientific understanding of fibromyalgia. With this data, it will be clear why fibromyalgia pain has been notoriously resistant to standard treatments.

    Fortunately, there are some newer alternative pain relief treatments that specifically target the central nervous system sensitization. One of the best-studied is low-dose naltrexone (LDN), which calms activated glial cells and lowers the volume of pain signals transmitted to the brain.

    Several case studies of fibromyalgia patients using LDN in a specialty practice will be reviewed, each highlighting one important aspect of prescribing LDN for this specific population. One challenge to prescribing LDN to patients with fibromyalgia is that many utilize opiate-based medications to manage their symptoms. There are ways to overcome this, including using ultra low-dose naltrexone along with separating dosage times adequately to lessen any interactions.